EXTL3

Across TCGA pan-cancer cohorts, EXTL3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated EXTL3 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher EXTL3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated EXTL3 expression acts as an unfavorable survival marker, although some lineages such as GBM and LSCC show a favorable association.

HNSC, LUAD, and GBM are the cancer types where EXTL3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	III,IV	0.932	1.000	.035	13	view →
LUAD	OS	Median	All	0.567	0.853	.008	6	view →
GBM	OS	Quartile	All	0.996	0.708	.007	6	view →
LSCC	DFS	Median	III,IV	0.911	0.531	.021	5	view →
UCEC	OS	Tertile	II,III,IV	1.000	0.639	.047	4	view →
PDAC	OS	Quartile	II,III,IV	0.238	0.628	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

EXTL3–HNSC (OS)

Open the HNSC breakdown →